ZA200104713B - Amide compounds. - Google Patents
Amide compounds. Download PDFInfo
- Publication number
- ZA200104713B ZA200104713B ZA200104713A ZA200104713A ZA200104713B ZA 200104713 B ZA200104713 B ZA 200104713B ZA 200104713 A ZA200104713 A ZA 200104713A ZA 200104713 A ZA200104713 A ZA 200104713A ZA 200104713 B ZA200104713 B ZA 200104713B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- salt
- substituted
- cyclo
- Prior art date
Links
- -1 Amide compounds Chemical class 0.000 title description 10
- 150000003839 salts Chemical class 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 208000000044 Amnesia Diseases 0.000 claims description 5
- 208000031091 Amnestic disease Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000001769 aryl amino group Chemical group 0.000 claims description 5
- 230000006986 amnesia Effects 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000006319 alkynyl amino group Chemical group 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000003435 aroyl group Chemical group 0.000 claims 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical class NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP8180A AUPP818099A0 (en) | 1999-01-14 | 1999-01-14 | New n-containing heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200104713B true ZA200104713B (en) | 2002-09-09 |
Family
ID=3812385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200104713A ZA200104713B (en) | 1999-01-14 | 2001-06-08 | Amide compounds. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6710043B1 (zh) |
| EP (1) | EP1140836B1 (zh) |
| JP (2) | JP3617454B2 (zh) |
| KR (2) | KR100525809B1 (zh) |
| CN (1) | CN1142910C (zh) |
| AR (1) | AR028812A1 (zh) |
| AT (1) | ATE502923T1 (zh) |
| AU (1) | AUPP818099A0 (zh) |
| BR (1) | BRPI0008753B8 (zh) |
| CA (1) | CA2360360C (zh) |
| CZ (1) | CZ20012562A3 (zh) |
| DE (1) | DE60045759D1 (zh) |
| ES (1) | ES2363492T3 (zh) |
| HK (1) | HK1044337B (zh) |
| HU (1) | HU230422B1 (zh) |
| IL (2) | IL143841A0 (zh) |
| RU (1) | RU2208608C2 (zh) |
| TR (1) | TR200102038T2 (zh) |
| TW (1) | TWI229075B (zh) |
| WO (1) | WO2000042011A1 (zh) |
| ZA (1) | ZA200104713B (zh) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| US20040029894A1 (en) * | 2000-12-07 | 2004-02-12 | Nobuya Matsuoka | Nootropic effect enhancer |
| WO2003049736A1 (en) * | 2001-12-11 | 2003-06-19 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| AU2003296366B2 (en) * | 2002-12-06 | 2010-01-21 | It Technologies Services, S.A. | Synergistic compositions |
| EP1608319A4 (en) * | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| ZA200703613B (en) | 2004-10-20 | 2009-05-27 | Univ California | Improved inhibitors for the soluble epoxide hydrolase |
| CA2579227A1 (en) * | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| SI1940786T1 (sl) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Ltd | Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C |
| TW200808723A (en) | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| TW200815353A (en) | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| EP2081898A2 (en) * | 2006-10-20 | 2009-07-29 | Arete Therapeutics, INC. | Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
| AU2007309117A1 (en) * | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Phenylurea compounds as soluble epoxide hydrolase inhibitors |
| GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| CN103251592B (zh) | 2007-04-20 | 2015-07-29 | 千寿制药株式会社 | 轴突形成促进剂 |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| SI2207775T1 (sl) | 2007-11-05 | 2012-05-31 | Novartis Ag | benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza |
| CA2707651A1 (en) | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| WO2011060321A1 (en) | 2009-11-16 | 2011-05-19 | Chdi, Inc. | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4939679B1 (zh) * | 1969-06-30 | 1974-10-28 | ||
| US3647805A (en) | 1969-07-11 | 1972-03-07 | Kyorin Seiyaku Kk | Benzoylamino substituted 1-benzoyl-piperidines |
| BE791501A (fr) * | 1971-11-19 | 1973-05-17 | Albert Ag Chem Werke | Diamines cycliques n,n'-disubstituees et leur procede de preparation |
| GB1416872A (en) * | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| JPS5152176A (zh) * | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
| DE2860314D1 (en) * | 1977-11-24 | 1981-02-19 | Synthelabo | Derivatives of naphthalene, process for their preparation and their therapeutic application |
| US4886809A (en) | 1986-07-31 | 1989-12-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
| CA1322199C (en) * | 1987-07-15 | 1993-09-14 | Masami Eigyo | N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia |
| JPH0696575B2 (ja) * | 1987-09-17 | 1994-11-30 | 三菱化成株式会社 | ４−アミノピリジン誘導体及びその酸付加塩 |
| US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| GB8917687D0 (en) * | 1989-08-02 | 1989-09-20 | Fujisawa Pharmaceutical Co | Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| CA2077252C (en) * | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| KR100238346B1 (ko) | 1993-04-07 | 2000-03-02 | 오쓰까 아끼히꼬 | 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제 |
| CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| DE4319038A1 (de) * | 1993-06-08 | 1994-12-15 | Bayer Ag | Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung |
| ATE204264T1 (de) * | 1993-06-18 | 2001-09-15 | Fujisawa Pharmaceutical Co | Zwischenprodukt zur verwendung in der synthese und verfahren zur herstellung eines aminopiperazinderivates |
| US5500423A (en) * | 1994-09-09 | 1996-03-19 | Hoechst-Roussel Pharmaceuticals Inc. | 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines |
| AU5432696A (en) * | 1995-04-07 | 1996-10-23 | Pharmacopeia, Inc. | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
| GB9519077D0 (en) * | 1995-09-18 | 1995-11-15 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| US6077857A (en) * | 1995-11-13 | 2000-06-20 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| FR2744449B1 (fr) * | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| ZA9710872B (en) * | 1996-12-12 | 1998-06-15 | Fujisawa Pharmaceutical Co | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate. |
| CA2275318A1 (en) * | 1996-12-24 | 1998-07-02 | Fujisawa Pharmaceutical Co., Ltd. | New use of aminopiperazine derivatives |
| WO1998035951A2 (en) | 1997-02-17 | 1998-08-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminopiperazine derivatives |
| US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
-
1999
- 1999-01-14 AU AUPP8180A patent/AUPP818099A0/en not_active Abandoned
- 1999-12-27 TW TW088123003A patent/TWI229075B/zh not_active IP Right Cessation
-
2000
- 2000-01-06 CZ CZ20012562A patent/CZ20012562A3/cs unknown
- 2000-01-06 KR KR10-2001-7007314A patent/KR100525809B1/ko active IP Right Grant
- 2000-01-06 HU HU0105108A patent/HU230422B1/hu not_active IP Right Cessation
- 2000-01-06 TR TR2001/02038T patent/TR200102038T2/xx unknown
- 2000-01-06 ES ES00900121T patent/ES2363492T3/es not_active Expired - Lifetime
- 2000-01-06 US US09/869,962 patent/US6710043B1/en not_active Expired - Lifetime
- 2000-01-06 RU RU2001122727/04A patent/RU2208608C2/ru active
- 2000-01-06 CA CA002360360A patent/CA2360360C/en not_active Expired - Lifetime
- 2000-01-06 JP JP2000593579A patent/JP3617454B2/ja not_active Expired - Lifetime
- 2000-01-06 KR KR10-2004-7009661A patent/KR100520406B1/ko active IP Right Grant
- 2000-01-06 DE DE60045759T patent/DE60045759D1/de not_active Expired - Lifetime
- 2000-01-06 IL IL14384100A patent/IL143841A0/xx active IP Right Grant
- 2000-01-06 BR BRPI0008753A patent/BRPI0008753B8/pt not_active IP Right Cessation
- 2000-01-06 WO PCT/JP2000/000017 patent/WO2000042011A1/en not_active Application Discontinuation
- 2000-01-06 AT AT00900121T patent/ATE502923T1/de active
- 2000-01-06 CN CNB008027455A patent/CN1142910C/zh not_active Expired - Lifetime
- 2000-01-06 EP EP00900121A patent/EP1140836B1/en not_active Expired - Lifetime
- 2000-01-12 AR ARP000100123A patent/AR028812A1/es not_active Application Discontinuation
-
2001
- 2001-06-08 ZA ZA200104713A patent/ZA200104713B/en unknown
- 2001-06-19 IL IL143841A patent/IL143841A/en not_active IP Right Cessation
-
2002
- 2002-08-13 HK HK02105923.9A patent/HK1044337B/zh not_active IP Right Cessation
-
2003
- 2003-05-12 JP JP2003132491A patent/JP2004002414A/ja not_active Withdrawn
- 2003-07-15 US US10/618,743 patent/US20040014745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200104713B (en) | Amide compounds. | |
| DE69532811T2 (de) | Heterocyclische Derivative und Arzneimittel | |
| MY123310A (en) | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions | |
| CA2488167A1 (en) | Prodrugs of excitatory amino acids | |
| MY112110A (en) | Novel 1,2,4-triazolo [1,5 a] pyrimidine compounds, their pharmaceutical compositions and use in the treatment of neurological disorders,and processes for their preparation. | |
| JP2008521780A (ja) | ２−アルコキシ−３，４，５−トリヒドロキシアルキルアミド系化合物、この調製、これを含有する組成物、および、この使用 | |
| WO2010013242A1 (en) | Substituted pyridoxine-lactam carboxylate salts | |
| US6284760B1 (en) | Method of treating schizophrenia, depression and other neurological conditions | |
| EP0285219B1 (en) | Method of improving sleep | |
| DE60209806T2 (de) | 2-amino-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase | |
| US7282515B2 (en) | Derivatives of azaspiro compounds for the treatment of pain | |
| KR910004559A (ko) | 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체 | |
| CA2452920C (en) | Benzo [g] quinoline derivatives for treating glaucoma and myopia | |
| MX9707596A (es) | Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo. | |
| DE2032687A1 (en) | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa | |
| AU719119B2 (en) | Benzo{g}quinoline derivatives | |
| US20090227557A1 (en) | Substituted beta-lactams | |
| DE69732359T2 (de) | Disubstituierte morpholin-, oxazepin- oder thiazepinderivate, deren herstellung und verwendung als dopamin-d4-rezeptorantagonisten | |
| CA2263100A1 (en) | Pharmaceutically active compounds and methods of use | |
| AU2002328856A1 (en) | Benzo (G) quinoline derivatives for treating glaucoma and myopia | |
| EP2116236A1 (en) | Bisbenzamidine derivatives for use as antioxidant | |
| HU205931B (en) | Process for producing pyrrolo-pyrimidine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active components | |
| US5196415A (en) | 5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of epilepsy and cocaine addiction | |
| JP2004524292A5 (zh) | ||
| CA2433667A1 (en) | Prodrugs of excitatory amino acids |